This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
Accept
Decline

ABOUT ACEPODIA®

Acepodia is a clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) for cancer treatment. The Company is focused on its proprietary AD2C™ platform and its lead clinical candidate, ACE723, a GPC3-targeted dual-payload ADC.

TECHNOLOGY

  • AD2C™
  • AD2C™
    TECHNOLOGY

    AD2C™

    Antibody-Dual-Drugs Conjugation (AD2C™) platform

    Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C™) platform which easily plug-and-plays multiple types of linker-payloads through site-specific conjugation process without compromising conjugation efficiency and casting minimal impact on antibody binding capacity. This platform has potential to increase the targeted delivery with improved efficacy.

PIPELINE

AD2C™

Program
Discovery
Preclinical
Phase I
Phase II
AD2C™-Oncology
ACE723
Phase I ​

LATEST NEWS

ADVANCING THE NEXT GENERATION OF IMMUNOTHERAPY